Objective. To evaluate radiographic subchondral trabecular bone texture (TBT) as a predictor of clinically relevant osteoarthritis (OA) progression (combination of symptom and structural worsening).
Trabecular bone texture (TBT) analysis is a method of determining the state of the vertical and horizontal trabeculae of a standardized region of interest of bone. Baseline TBT of the subchondral tibial bone in cohorts with knee osteoarthritis (OA) has been shown to predict OA structural progression, as defined by radiography and/or magnetic resonance imaging (MRI), over the ensuing 12-48 months (1) (2) (3) , as well as knee joint replacement (4) and incident OA (5) . TBT also changes concurrently with loss of joint space width (JSW), joint space area, and cartilage volume on MRI in knee OA progression (1, 2) . Notably, TBT has not previously been evaluated for its ability to predict pain progression or the combination of pain progression and structural progression.
TBT data are generated from a plain knee radiograph using a method known as fractal signature analysis based on prior work by Dr. Buckland-Wright (6) (summarized in ref. 1) . TBT is a particularly attractive potential means of enriching OA trials for progressors since it can be generated from data extracted from the types of screening knee radiographs already standard in any knee OA clinical trial. In all fields, trial enrichment markers significantly improve the chances for successful phase transitions, the probability that a drug candidate will advance into the next phase of development (7) . It is estimated that 2 in 4 phase III trials without selection biomarkers will fail versus only 1 in 4 trials with selection biomarkers (7) .
The reasons for the translational failure of anti-OA drugs are multifold. They include the poor relationship between joint structural pathology (especially joint space narrowing [JSN] on radiographs) and symptomatic disease in individual patients, the limited responsiveness of existing biomarkers (8) , the existence of multiple phenotypes of OA that may each require somewhat different approaches for optimizing treatment (9) , and the phasic progression of OA (10) that results in enrollment of low numbers of progressors in the absence of effective enrichment strategies. A secondary analysis of a failed phase III clinical trial of risedronate for knee OA demonstrated the potential utility of biomarkers (11) . Although risedronate failed to demonstrate superiority in the attenuation of knee OA structural deterioration based on JSN in that trial, C-telopeptide of type II collagen (CTX-II) levels decreased with risedronate therapy, and urinary concentrations of CTX-II at 6 months correlated with radiologic progression at 24 months. TBT analyses in that trial demonstrated a dose-dependent therapeutic drug effect characterized by retention of normal trabecular structure in the knees of progressors with JSN (12) . Even a modest strategy of enriching a trial for OA progressors or reducing screen failure rates (i.e., risedronate trials had a screen failure rate of 73% [13] ) could have significant cost implications. Not surprisingly, a European League Against Rheumatism committee of OA researchers, clinicians, and patients has listed identification of predictors of OA progression as a high research priority, especially where this might enable stratified interventions (14) .
Other than knee alignment, meniscal pathology, bone marrow lesions, synovitis, and frequent knee pain (15) (16) (17) (18) , there are currently few validated alternatives for enriching OA trials for structural progressors. The data acquired by MRI (related to the meniscus, bone marrow, and synovium) are relatively costly and sometimes inaccessible. The inexpensive and readily accessible data traditionally relied upon to identify progressors, such as the OA risk factors of age, sex, and body mass index (BMI), have been shown to be poor predictors in a heterogeneous population of OA patients (1, 19, 20) .
The objective of our study was to investigate the ability of baseline and short-term (over 12-24 months) radiographic medial subchondral TBT to predict clinically relevant medial knee OA progression (a combination of symptom and structural worsening) over 48 months. We hypothesized that TBT could be a valuable adjunct for enriching OA clinical trials for clinically relevant progressor subjects, thereby providing a means of increasing study power and potentially reducing study costs or enhancing trial efficiency due to the need to enroll fewer trial participants.
PATIENTS AND METHODS
Study design. The Foundation for the National Institutes of Health (FNIH) OA Biomarkers Consortium undertook a nested case-control study (194 cases and 406 OA comparators) of progressive knee OA within the Osteoarthritis Initiative, a unique longitudinal cohort with a publicly available repository of joint images, biologic specimens, and clinical data obtained at annual clinic visits (21) . Details of the study design have been published previously (21, 22) . Briefly, participants eligible for the present study were those who had at least 1 knee with a Kellgren/Lawrence (K/L) grade of 1-3 (23) at baseline determined at a central reading site and for whom knee radiographs, knee MRIs, stored serum and urine specimens, and clinical data were available for the baseline and 24-month visits. One index knee was selected for each participant. Participants were excluded if they had a knee or hip replacement between baseline and 24 months or had radiographic or pain progression at the 12-month follow-up. Knees that had a lateral JSN grade of ≥2 at baseline were excluded.
Radiography. Radiography of both knees was performed at all clinic visits using the same nonfluoroscopic fixed-flexion protocol (SynaFlexer; Synarc) (24) . Radiographs were assessed for K/L grade at the central reading site (23) . The minimum JSW in the medial femorotibial compartment was measured using automated software (25) . Knees were excluded for poor radiographic positioning (defined by baseline medial compartment rim distance of >6.5 mm or change in rim distance of >2.0 mm from baseline to all follow-up time points) because such knees would make measurement of minimum JSW unreliable.
Definitions of radiographic and symptomatic progression. Radiographic progression was defined as a loss of ≥0.7 mm in medial minimum JSW from baseline to 24, 36, or 48 months. Knee pain was assessed using the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale (26) . Based on an established minimum clinically important difference (MCID) for pain worsening (27) , persistent pain progression was defined as a pain increase of ≥9 points at 2 or more time points (on a 0-100 normalized scale) from the 24-month pain assessment to the 60-month pain assessment. (The 60-month time point was assessed to verify pain persistence if the pain worsening end point was reached at 48 months.)
Two main outcome groups were defined. Case knees (n = 194) had clinically relevant (both radiographic and pain) progression, and comparator OA knees (n = 406) lacked the combination of radiographic and pain progression. Comparator knees could be subdivided into 3 groups: those with radiographic progression but not pain progression (n = 103); those with pain progression but not radiographic progression (n = 103); and OA nonprogressors (n = 200), who had neither radiographic progression nor pain progression in the index knee and no joint space loss or pain progression in the contralateral knee. For better covariate balance among the groups, the knees selected for the 4 groups were frequency matched, using K/L grade strata (for grades 1-3) and BMI strata <25, 25 to <27.5, 27.5 to <30, 30 to <35, and ≥35 kg/m 2 . Determination of TBT. TBT data were extracted from the same nonfluoroscopic fixed-flexion knee radiographs used for K/L grade and JSW determinations. Radiographic analyses were performed using validated and commercially available semiautomated software (KneeAnalyzer; Optasia Medical). The software provides a complex data set of variables (fractal dimension and radius) from the medial tibial subchondral bone of the knee that can be used to plot fractal signature curves ( Figure 1 ). The software uses a horizontal filter (HF) to generate data on the vertical trabeculae and a vertical filter (VF) to generate data on the horizontal trabeculae. Figure 1 . Graphic representation of fractal signature curves at baseline, 12 months, and 24 months. Fractal signature curves are generated by plotting the fractal dimension versus the radius. Top, Fractal signature curves derived from the horizontal filter of KneeAnalyzer software at baseline. The horizontal filter yields information about the vertical trabeculae. Bottom, Fractal signature curves derived from the vertical filter of KneeAnalyzer software at baseline. The vertical filter yields information about the horizontal trabeculae. Line graphs show mean (raw unadjusted) data on subjects with observations at all 3 time points. Orange lines depict the mean fractal signature curves for primary cases (subjects with knee osteoarthritis [OA] with radiographic and pain progression from 24 to 48 months after baseline); blue lines depict the mean fractal signature curves for primary comparators (subjects with knee OA that did not meet the primary case definition).
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KRAUS ET AL Our novel data reduction method relies on a global shape analysis of the fractal signature curves and enabled us to convert the very complex fractal signature data from the medial compartment of each knee radiograph into 6 TBT parameters: HF intercept, HF linear slope, HF quadratic slope, VF intercept, VF linear slope, and VF quadratic slope. These parameters are suitable for subsequent regression and receiver operating characteristic (ROC) curve analyses. Global shape analysis of the fractal signature curves was performed using mixed models (28) (assuming an autoregressive error structure). The empirical best linear unbiased estimate was derived for the mode including the linear slope and quadratic polynomials of radius.
In slight contrast to our prior work, extraction of the TBT parameters for these analyses originated from the nadir (and center) of the fractal signature curves to reduce the correlation between the estimated parameters. The advantage of this refinement has been to create near orthogonal (non-overlapping, independent) TBT parameters more suitable for multivariable and combinatorial statistical modeling and allowing the researcher to assess which parameter relates most to the outcomes under study. The absolute values of the parameters are therefore not directly comparable to prior published work but their ability to be predictive of outcomes should be as good, and their potential use in combination improved due to the reduction of multicollinearity. The interrater reliability of TBT is very high, as previously reported (1). To minimize confusion, all results are reported with reference to the horizontal or vertical filter from which they were generated.
Statistical analysis. In total, 579, 551, and 569 radiographs of suitable quality for TBT analyses were available at baseline, 12 months, and 24 months, respectively. TBT analyses were based on baseline data and time-integrated values over 12 months (n = 538) and 24 months (n = 554). The prespecified primary analyses evaluated the ability of the 6 individual TBT parameters to predict case status (those with both pain progression and radiographic [joint space loss] progression; n = 194) versus comparator status (those without both pain progression and radiographic progression; n = 406).
The 4 prespecified secondary analyses compared the best (based on univariable modeling) TBT parameter (VF linear slope) by each type of progressor status. Method 1 compared subgroups with pain progression and joint space loss progression, pain progression only, and joint space loss progression only to the nonprogressor reference group (who had neither radiographic progression nor pain progression). Method 2 compared all progressors (radiographic or pain) to the nonprogressors. Method 3 compared all radiographic progressors to radiographic nonprogressors. Method 4 compared all pain progressors to pain nonprogressors.
The main analysis used multivariable regression with TBT parameters transposed to Z scores (created by subtracting the value for a subject from the total group mean and dividing by the standard deviation) in order for 1 unit of change to be comparable across the parameters; thereby a Z score of 0 represents the sample mean. This strategy overcomes the challenge of comparing measures that have different ranges. Analyses were adjusted for covariates including age, sex, BMI, race, baseline radiographic JSW, baseline K/L grade, baseline knee pain, and use of pain medications.
The best composite TBT score was derived by combining the Z scores of the 3 TBT parameters predictive in univariable models. Two of the TBT parameters that predicted case status (VF linear slope and VF quadratic slope) had negative Z scores, and therefore, they were reverse coded (sign changed) before they were summed with the HF intercept (for which positive Z scores predicted case status) to create a composite score. ROC curve (C statistic) analysis was used to determine the predictive capability of the parameters. Parameters were evaluated individually or as a composite of 3 parameters. In addition to baseline values, TBT parameters were expressed in terms of timeintegrated values over 12 months and 24 months from baseline; these measures are equivalent to the area under the curve defined by the individual values for the specific time interval.
RESULTS

Participant characteristics and TBT parameters.
The demographic characteristics of the participants selected for these analyses are listed in Table 1 Primary analyses with TBT parameters. Relative to primary comparators, primary cases were characterized by higher HF and lower VF fractal dimensions (Figure 1 ), reflecting thinner (more complex) vertical trabeculae and thicker (less complex) horizontal trabeculae, respectively. Over 12 months and 24 months, HF intercept and VF linear slope were both significantly associated with case status. HF intercept was positively associated with case status, while VF linear slope was negatively associated with case status. Over 12 months, VF quadratic slope was negatively associated with case status ( Table 2 ). The summed composite of these 3 TBT parameters (as Z scores with reverse coding of the 2 slope components) at baseline and over 12 months and 24 months predicted case status with odds ratios (ORs) ranging from 1.24 to 1.43 (Table 2) . Using the composite score, the C statistic for predicting case status improved modestly but significantly (0.633-0.649) over the use of the covariates alone (0.608).
Secondary analyses with TBT parameters. The TBT parameters were further evaluated for their ability to predict the group into which an individual would be classified at 48 months, namely, any progression, joint space loss (radiographic) progression, or pain progression. In each instance, VF linear slope was the best single and significant TBT predictor, and was negatively associated with case status, for each type of progression (Table 3) . VF linear slope best predicted pain progression, with the C statistic reaching 0.654 based on VF linear slope over 24 months. 
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DISCUSSION
These results represent the fourth major validation of TBT as a predictor of OA progression, determined radiographically (1, 3, 29) , by MRI (29) , and, in our analysis, by a combination of symptom and radiographic worsening. We noted that, consistent with all prior analyses, progressor cases were characterized by trabecular remodeling of both horizontal (thicker) and vertical (thinner and more complex) trabeculae of the medial tibial subchondral bone compartment of the affected knee. Prior work suggested that individuals at risk of progressive OA have baseline TBT characteristics that reflect stress shielding of vertical trabeculae by thickened horizontal trabeculae, resulting in apparently thin vertical trabeculae due to their hypomineralization as a result of high subchondral bone turnover (1,2). Buckland-Wright, the first to apply TBT methodology to the study of OA, considered increased horizontal trabecular thickness to be representative of early OA that preceded later changes in vertical trabeculae (6) .
Horizontal trabecular thickening is intuitively consistent with traditional observations associating radiographic subchondral sclerosis with OA and OA progression. In this cohort study, thickening of the horizontal trabeculae was the characteristic most predictive of the risk of OA progression and consistent with the inclusion of subjects with early OA (12-13% with K/L grade 1; all patients had to have a baseline JSW ≥0.7 mm, regardless of baseline K/L status; there were no subjects with K/L grade 4). Also, compatible with the observation by Buckland-Wright that changes in vertical trabeculae were indicative of later OA, our prior study (1) , showing greater changes in the vertical trabecular structures, was skewed toward more severe knee OA at baseline, with 10% of the included knees having a K/L grade of 4.
The VF linear slope was the most predictive of primary case status and predicted all types of progression, including radiographic progression only and pain progression only. In secondary analyses, the strongest odds were observed for TBT (VF linear slope) prediction of OA progression based on the combination of pain and structural worsening (OR 0.71). As shown by a recent systematic review, subchondral bone features have independent associations with structural progression, pain progression, and joint replacement in peripheral OA, especially in the knee (30) . These data support the increasing acceptance of the role of bone in both disease and illness aspects of OA disease progression. Although in primary analyses no baseline single variable was associated with case status, the baseline composite score of 3 variables was significantly predictive of case status. Moreover, baseline TBT parameters showed the same trends as the significant TBT 12-month and 24-month time-integrated values, and baseline VF linear slope predicted any progression (all radiographic and/or pain progressors versus nonprogressors). Compared to baseline TBT, the greater predictive capability of 12-month and 24-month time-integrated values (more proximal to the 24-48 month end point timeframe) for predicting case status, pain, and structural progression is consistent with TBTas an indicator of proximal events.
In contrast to prior studies, TBT parameters in the present study were computed from the nadir of the fractal signature curves to generate parameters that more closely yielded nonoverlapping, i.e., orthogonal, data. Using this new method, we were able for the first time to evaluate the utility of the TBT intercept parameters. Interestingly, in addition to VF linear slope and VF quadratic slope terms, the HF intercept contributed useful information to a composite of 3 TBT parameters for predicting primary case status.
There are several limitations of our study that are worth noting. For one, the method of extraction of TBT parameters from fractal signature curves was slightly different from that of previously published studies, so the TBT parameters are not directly comparable. Efforts to standardize methods would be desirable; otherwise, comparability across studies will be an ongoing challenge. We did not include data for the lateral compartment because medial compartment dominant knee OA was a requirement for study inclusion. A recent study demonstrated that the inclusion of lateral compartment data in predictive models, although not as strong as medial compartment data, provided the best predictive model (3). In addition, no effort was made in this first-phase biomarker qualification study to control Type I error. It was curious that a higher level of baseline pain was associated with lower odds of being a case; this might mean that knees with higher pain levels at baseline were less likely to have met the MCID for pain worsening. Finally, participants in the main study were excluded based on radiographic progression and pain progression during the first 12 months of follow-up in an attempt to identify prognostic biomarkers in contrast to correlative biomarkers changing concurrently with progression. However, these rapid progressors may be the subjects most likely to be identified by TBT, so their exclusion could have lowered the apparent prognostic capability of this imaging biomarker.
The best predictive capability displayed by TBT parameters for primary case status in our study (C statistic 0.654) was lower than in all previous studies. This may be because the comparators in our primary analysis included some noncomposite (radiographic only and pain only) progressors. The confirmation of this possibility was not borne out by secondary analyses that compared different progressor groups, suggesting that the exclusion of individuals with radiographic progression over the first 12 months of observation might better account for the differences in this and prior studies.
In summary, these results show that adding TBT to the currently used predictors will modestly increase the ability to predict knee OA progression. These results confirm the findings of previous studies and together suggest that baseline TBT might be used in an OA trial enrichment strategy as outlined in Food and Drug Administration guidance (31) . TBT could be especially attractive as a means of enriching OA trials for progressors since it can be generated from data extracted from the types of screening knee radiographs already standard in any knee OA clinical trial. Future work will evaluate various combinations of soluble biochemical and imaging biomarkers for the various ways of proceeding to advance OA-related biomarkers as drug development tools.
